Research Topics
| Phillip FebboSummaryAffiliation: Duke University Medical Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Gene expression correlates of clinical prostate cancer behaviorDinesh Singh
Department of Adult Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
Cancer Cell 1:203-9. 2002..These results support the notion that the clinical behavior of prostate cancer is linked to underlying gene expression differences that are detectable at the time of diagnosis...
Defining aggressive prostate cancer using a 12-gene modelTarek A Bismar
Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
Neoplasia 8:59-68. 2006..0015). This study demonstrates that cross-platform models can lead to predictive models with the possible advantage of being more robust through this selection process...
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expressionCarey K Anders
Duke University Medical Center, Box 3841, 3829 Duke South, Red Zone, Durham, NC 27710, USA
J Clin Oncol 26:3324-30. 2008..Breast cancer arising in young women is correlated with inferior survival and higher incidence of negative clinicopathologic features. The biology driving this aggressive disease has yet to be defined...- Literature Lab: a method of automated literature interrogation to infer biology from microarray analysisPhillip G Febbo
Institute for Genome Science and Policy, Duke University, Durham, North Carolina, USA
BMC Genomics 8:461. 2007..e. pathway names, medical subject heading (MeSH) terms, etc)... - Genomic approaches to outcome prediction in prostate cancerPhillip G Febbo
Department of Medicine Duke Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina, USA
Cancer 115:3046-57. 2009..Cancer 2009;115(13 suppl):3046-57. (c) 2009 American Cancer Society... - Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancerPhillip G Febbo
Duke Institute for Genome Sciences and Policy, Division of Medical Oncology Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Cancer Res 12:152-8. 2006.... - Genomic strategy for targeting therapy in castration-resistant prostate cancerPrateek Mendiratta
The Duke Institute for Genome Sciences and Policy, Duke Comprehensive Cancer Center, Duke University, Durham, NC 27710, USA
J Clin Oncol 27:2022-9. 2009..The variable response to secondary hormonal manipulations in men with castrate-resistant prostate cancer (CRPC) creates a compelling need for strategies to individualize therapy based on the molecular features of each patient's tumor... - Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancerDavid S Hsu
Division of Medical Oncology, Department of Medicine, Duke University, Durham, NC 27710, USA
J Clin Oncol 25:4350-7. 2007..We utilized a genomic strategy to develop signatures predictive of chemotherapeutic response to both cisplatin and pemetrexed to provide a rational approach to effective individualized medicine... - Cancer gene profiling in prostate cancerAdam Foye
Departments of Medicine and Molecular Genetics and Microbiology, Duke Institute for Genome Science and Policy, Duke University, Durham, NC, USA
Methods Mol Biol 576:293-326. 2010.... - Centralized biorepositories for genetic and genomic researchGeoffrey S Ginsburg
Center for Genomic Medicine, Duke Institute for Genome Sciences and Policy, Durham, NC 27708, USA
JAMA 299:1359-61. 2008 - Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatmentChristina K Augustine
Departments of Surgery, Duke University, Durham, NC 27710, USA
Cancer Res 68:3777-84. 2008..Targeted therapy using an N-cadherin antagonist can dramatically augment the antitumor effects of chemotherapy and is a novel approach to optimizing treatment for melanoma... - Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancerRichard F Riedel
Duke University Medical Center, Division of Hematology, Department of Medicine, Durham, NC 27710, USA
Future Oncol 1:461-6. 2005..This finding has extraordinary implications and serves as a critical step toward individualized, patient-specific treatment plans based on the molecular constitution of the tumor of each individual... - Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancersAndrew Berchuck
Department of Obstetrics and Gynecology Division of Gynecologic Oncology, Institute of Statistics and Decision Sciences, Center for Applied Genomics and Technology, Duke University Medical Center, Durham, North Carolina, USA
Clin Cancer Res 11:3686-96. 2005..The objective of this study was to define gene expression patterns associated with favorable survival... - Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literatureAndrew J Armstrong
Department of Medicine and Surgery, Duke Comprehensive Cancer Center, Durham, NC 27710, USA
Oncologist 14:816-27. 2009.... - A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancerAndrew J Armstrong
Duke Comprehensive Cancer Center and Duke Prostate Center, Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina 27710, USA
Clin Cancer Res 16:3057-66. 2010.... - Dunning rat prostate adenocarcinomas and alternative splicing reporters: powerful tools to study epithelial plasticity in prostate tumors in vivoSebastian Oltean
Department of Molecular Genetics and Microbiology, Duke University Medical Center, Research Drive, Box 3053 424 CARL, Durham, NC 27710, USA
Clin Exp Metastasis 25:611-9. 2008.... - A genomic strategy to elucidate modules of oncogenic pathway signaling networksJeffrey T Chang
Institute for Genome Sciences and Policy, Duke University Medical Center, Duke University, Durham, NC 27708, USA
Mol Cell 34:104-14. 2009.... - MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagyBala S Balakumaran
Duke Institute for Genome Sciences and Policy and Duke Comprehensive Cancer Center, Duke University, NC 27710, USA
Cancer Res 69:7803-10. 2009..Taken together, our findings suggest that MYC expression abrogates sensitivity to rapamycin through increased expression of 4EBP1 and reduced autophagy... - Immune signatures predict prognosis in localized cancerDavid S Hsu
Duke Institute for Genome Sciences and Policy, Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina, USA
Cancer Invest 28:765-73. 2010..05, HR = 0.62). In aggregate, the gene expression signatures implicating specific components of the immune response hold prognostic import across solid tumors... - A genomic approach to identify molecular pathways associated with chemotherapy resistanceRichard F Riedel
Duke Institute for Genome Sciences and Policy, Duke University, 2175 CIEMAS Building, Durham, NC 27710, USA
Mol Cancer Ther 7:3141-9. 2008..These results support the use of a genomic approach to identify drug-specific targets associated with the development of chemotherapy resistance and underscore the importance of disease context in identifying these pathways... - MYC activity mitigates response to rapamycin in prostate cancer through 4EBP1-mediated inhibition of autophagyBala S Balakumaran
Duke University, School of Medicine, Durham, NC, USA
Autophagy 6:281-2. 2010..It is likely that the genetic context of specific cancers will have an impact upon whether autophagy is primarily a mechanism for survival or cell death... - The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft modelJohn C Mavropoulos
Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
Cancer Prev Res (Phila) 2:557-65. 2009.... - Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastomaTracy Ann Read
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA
Cancer Cell 15:135-47. 2009..CD15 is also found in a subset of human medulloblastomas, and tumors expressing genes similar to those found in murine CD15(+) cells have a poorer prognosis. Thus, CD15 may represent an important marker for TPCs in medulloblastoma... - Genomic signatures associated with the development, progression, and outcome of prostate cancerPrateek Mendiratta
Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina, USA
Mol Diagn Ther 11:345-54. 2007..This framework has the exciting potential to be predictive and provide personalized and individual treatment to the large number of men diagnosed with prostate cancer each year... - New insights into prostate cancer biologyBala S Balakumaran
Duke Institute for Genome Sciences and Policy, Duke University, Durham, NC 27708, USA
Hematol Oncol Clin North Am 20:773-96. 2006..Such a characterization is likely to be required to maximize our ability to optimize and individualize preventive and treatment strategies... - Modeling cancer progression via pathway dependenciesElena J Edelman
Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina, USA
PLoS Comput Biol 4:e28. 2008..A novel finding of our analysis is a connection between ErbB4 and primary prostate cancer... - Analysis of sample set enrichment scores: assaying the enrichment of sets of genes for individual samples in genome-wide expression profilesElena Edelman
Institute for Genome Sciences and Policy, Duke University, Durham, NC 27708, USA
Bioinformatics 22:e108-16. 2006..AVAILABILITY: Versions are available in Octave and Java (with a graphical user interface). Software can be downloaded at http://people.genome.duke.edu/assess... - Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancerMichael Stanbrough
Cancer Biology Program, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
Cancer Res 66:2815-25. 2006..These results indicate that enhanced intracellular conversion of adrenal androgens to testosterone and dihydrotestosterone is a mechanism by which prostate cancer cells adapt to androgen deprivation and suggest new therapeutic targets... - Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT modelPradip K Majumder
Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 100:7841-6. 2003..Thus, the MPAKT model may be useful in studying the role of Akt in prostate epithelial cell transformation and in the discovery of molecular markers relevant to human disease... - Use of expression analysis to predict outcome after radical prostatectomyPhillip G Febbo
Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02118, USA
J Urol 170:S11-9; discussion S19-20. 2003..A critical next step will be to try and validate such findings in larger independent datasets... - Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumorsPamela L Paris
Comprehensive Cancer Center, University of California at San Francisco, 94115, USA
Hum Mol Genet 13:1303-13. 2004..Moreover, comparison with an independent set of metastases revealed approximately 40 candidate markers associated with metastatic potential. Copy number aberrations at these loci may define metastatic genotypes... - Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancerPhillip G Febbo
Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston Massachusetts 02115, USA
Clin Cancer Res 11:5233-40. 2005..No pathologic complete responses were observed. Altered androgen metabolism may partially account for the noted declines in prostate-specific antigen and be a mechanism for chemotherapy resistance... - Noise and bias in microarray analysis of tumor specimensPhillip G Febbo
J Clin Oncol 24:3719-21. 2006 - Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumorsJames V Alvarez
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Cancer Res 65:5054-62. 2005..Finally, we showed that STAT3 is required for the expression of these genes in a breast cancer cell line. Taken together, these results identify a cohort of STAT3 targets that may mediate its role in oncogenesis... - Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative diseaseJing Wang
Department of Pathology and Medicine, Howard Hughes Medical Institute, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
EMBO J 24:368-81. 2005..This model of MLL-CBP therapy-related myeloproliferative disease demonstrates the selectivity of this MLL fusion for GMP cells and its ability to initiate leukemogenesis in conjunction with cooperating mutations... - Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNPMarshall E Lieberfarb
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
Cancer Res 63:4781-5. 2003..This organizational strategy revealed apparently distinct genetic subsets of prostate cancer... - Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancerPhillip G Febbo
Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
J Urol 173:1772-7. 2005.... - mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathwaysPradip K Majumder
Department of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Nat Med 10:594-601. 2004.... - Androgen-induced differentiation and tumorigenicity of human prostate epithelial cellsRaanan Berger
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
Cancer Res 64:8867-75. 2004..These observations indicate that androgen receptor expression is oncogenic and addictive for the human prostate epithelium... - Stromally expressed c-Jun regulates proliferation of prostate epithelial cellsWenhua Li
Department of Urology, Massachusetts General Hospital, Harvard Medical School, Yawkey Bdlg, Suite 7E, 55 Fruit St, Boston, MA 02114 2354, USA
Am J Pathol 171:1189-98. 2007..Identification of the signal transduction pathways between prostate epithelial cells and the surrounding stromal cells will improve our understanding of the normal and abnormal biology in prostatic diseases...
Research Grants
- Expression Analysis of Prostate CancerPhillip Febbo; Fiscal Year: 2006....
- mTOR Therapy in Prostate Cancer: Signatures of Response and Biology of ResistancePhillip Febbo; Fiscal Year: 2007..While focused on mTOR response in metastatic prostate cancer, the methods developed and tested in this proposal can be broadly applied. ..
- mTOR Therapy in Prostate Cancer: Signatures of Response and Biology of ResistancePhillip Febbo; Fiscal Year: 2009..While focused on mTOR response in metastatic prostate cancer, the methods developed and tested in this proposal can be broadly applied. ..
- mTOR Therapy in Prostate Cancer: Signatures of Response and Biology of ResistancePhillip G Febbo; Fiscal Year: 2010..While focused on mTOR response in metastatic prostate cancer, the methods developed and tested in this proposal can be broadly applied. ..